ERBB2 and neoplasm: Our results showed that 4/28 tumours were negative for PTEN (indicative of gene mutation), and 3/4 of these tumours showed objective response to treatment with CCI-779; 3/28 tumours had HER-2 gene overexpression (3+ Herceptin Test or FISH +ve), 2/3 of these tumours showed an objective response to the drug.